3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by The University of Texas Health Science Center at San Antonio
Information provided by (Responsible Party):
Javier Hernandez, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
First received: February 3, 2011
Last updated: March 19, 2015
Last verified: March 2015

The investigators will propose a novel method to improve prostate cancer screening with PSA, using a 3-month treatment with finasteride, a drug used to treat Benign Prostatic Hyperplasia (BPH) and proven to reduce a man's risk of developing prostate cancer. The investigators will also examine three additional promising tests that may further improve diagnosis of prostate cancer.

Condition Intervention Phase
Prostate Cancer
Drug: Finasteride
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Screening
Official Title: Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test

Resource links provided by NLM:

Further study details as provided by The University of Texas Health Science Center at San Antonio:

Primary Outcome Measures:
  • Determine if finasteride improves the Prostate Specific Antigen (PSA) and the Digital Rectal Exam (DRE) for prostate cancer screening by reducing the PSA and the size of the prostate. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Participants will take Finasteride/Placebo 5mg per day by mouth for 3 months before prostate biopsy.

Estimated Enrollment: 500
Study Start Date: February 2011
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Finasteride
Finasteride 5mg tablets every day by mouth for 3 months
Drug: Finasteride
Finasteride 5mg every day by mouth for 3 months
Other Names:
  • Proscar®
  • Propecia®
Placebo Comparator: Placebo
Placebo 5mg tablet every day by mouth for 3 months

Detailed Description:

The primary goal of this proposal is to determine if a 5-alpha reductase 'challenge' improves screening performance of PSA and DRE in men who are scheduled for prostate biopsy. Currently a higher PSA level leads to a recommendation for prostate biopsy, causing hundreds of thousands of unnecessary biopsies annually in the U.S. We will show that a three-month treatment with finasteride for men with high PSA levels will better predict the man who should have a prostate biopsy. PSA performance after finasteride 'challenge' will also be compared with new tests for prostate cancer. Finasteride is supplied by Merck and Company, Incorporated.


Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Risk of prostate cancer 20-60% calculated with the on-line Prostate Cancer Prevention Trial (PCPT) prostate cancer risk calculator. (www.prostate-cancer-risk-calculator.com). PSA value must be obtained within 3 months prior to study entry. A description of the frequency of these individuals in the population is provided in Specific Aim 2
  2. Patient has been recommended to undergo and plans to have a prostate biopsy.
  3. Patient is willing to delay prostate biopsy for a 3-month finasteride vs placebo treatment.
  4. No allergy to finasteride or other five alpha reductase inhibitors.
  5. Patient is willing to take finasteride vs placebo 5 mg orally daily for 3-month treatment period.
  6. Age 55 or older. (This age is selected as the PCPT risk calculator is only valid for this age range.)

Exclusion Criteria:

  1. Risk of cancer greater than 60% or less than 20%.
  2. Prior history of prostate cancer.
  3. Prior treatment with finasteride or dutasteride in the past 6 months
  4. Younger than age 55.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01296672

Contact: Joseph Long (210) 450-0754 longj4@uthscsa.edu

United States, Texas
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center Recruiting
San Antonio, Texas, United States, 78229
Contact: Joseph Long    210-450-0754    longj4@uthscsa.edu   
Principal Investigator: Javier Hernandez, MD         
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Principal Investigator: Javier Hernandez, MD The University of Texas Health Science Center at San Antonio
  More Information

No publications provided

Responsible Party: Javier Hernandez, Associate Professor, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT01296672     History of Changes
Other Study ID Numbers: ROI10-352, R01CA138627
Study First Received: February 3, 2011
Last Updated: March 19, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by The University of Texas Health Science Center at San Antonio:
Prostate cancer
Prostate Specific Antigen (PSA)
Men at intermediate risk of prostate cancer
Men scheduled for prostate biopsy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Genital Diseases, Male
5-alpha Reductase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Urological Agents

ClinicalTrials.gov processed this record on September 02, 2015